Several possible studies
Story checked
Osteoboost: FDA-Cleared Device for Osteopenia Treatment (opens in a new tab)
osteoboost.com · 2026-07-27
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Osteoboost: FDA-Cleared Device for Osteopenia Treatment
osteoboost.com · 2026-07-27
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedOsteoboost is the only FDA-cleared wearable belt using NASA-inspired vibration therapy to fight osteopenia in postmenopausal women.View evidenceHide evidence
As statedonly FDA-cleared
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 4Not checkedThe article says a randomized, sham-controlled clinical trial recently published in JBMR Plus found that women using Osteoboost at least three times per week over a year had an average 85% reduction in bone loss compared with the control group.View evidenceHide evidence
As stated85% reduction in bone loss
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 4Not checkedThe device is worn for 30 minutes daily and delivers low-level vibrations calibrated within 20-40 Hz and 0.1-0.3 g to stimulate the hips and spine.View evidenceHide evidence
As stated30 minutes daily; 20-40 Hz and 0.1-0.3 g
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 4Not checkedThe article says the FDA cleared Osteoboost through the De Novo pathway and designated it a Breakthrough Device, and that it is now being prescribed to women with osteopenia due to menopause.View evidenceHide evidence
As statedDe Novo pathway; Breakthrough Device
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
PubMed, Europe PMC, Crossref · 15 candidate papers
Evolving strategies for osteoporosis management in postmenopausal women: From tradition to innovation.
Medicine · 2025 · PubMed, Europe PMC
Effectiveness of Calcium and Vitamin D, With and Without Collagen Peptide, in Enhancing Bone Mineral Density on Postmenopausal Women with Osteopenia: A Randomized Controlled Trial
Annals of Punjab Medical College · 2025 · Crossref
Response to Letter to the Editor for "Benefits of targeted vibration for bone strength and bone density in postmenopausal women with osteopenia: a randomized, sham-controlled trial".
JBMR Plus · 2025 · PubMed, Europe PMC, Crossref
Peer Review #2 of "Proteomic profiling analysis of postmenopausal osteoporosis and osteopenia identifies potential proteins associated with low bone mineral density (v0.2)"
2020 · Crossref
Concerns about the paper, "Benefits of targeted vibration for bone strength and bone density in postmenopausal women with osteopenia: a randomized, sham-controlled trial".
JBMR Plus · 2025 · PubMed, Europe PMC, Crossref
And 10 more candidates considered.